loading...| Preferred Name | Certolizumab Pegol | |
| Synonyms |
|
|
| Definitions |
A Fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and conjugated to polyethylene glycol (PEG), with anti-inflammatory activity. Upon administration, certolizumab binds to TNF-alpha and prevents the interaction of this cytokine with endogenous cell surface receptors, thereby rendering TNF-alpha inactive and inhibiting TNF-mediated inflammatory responses. TNF-alpha is a protein involved in inflammation, cell survival, and apoptosis. Pegylation of certolizumab allows for an improved pharmacokinetic profile. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C80972 |
|
| CAS_Registry |
428863-50-7 |
|
| CHEBI_ID |
CHEBI:63585 |
|
| Chemical_Formula |
C19H30N5O8S(C2H4O)n(C2H4O)n |
|
| code |
C80972 |
|
| Contributing_Source |
FDA |
|
| definition |
A Fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and conjugated to polyethylene glycol (PEG), with anti-inflammatory activity. Upon administration, certolizumab binds to TNF-alpha and prevents the interaction of this cytokine with endogenous cell surface receptors, thereby rendering TNF-alpha inactive and inhibiting TNF-mediated inflammatory responses. TNF-alpha is a protein involved in inflammation, cell survival, and apoptosis. Pegylation of certolizumab allows for an improved pharmacokinetic profile. |
|
| FDA_UNII_Code |
UMD07X179E |
|
| in_subset | ||
| label |
Certolizumab Pegol |
|
| Legacy Concept Name |
Certolizumab_Pegol |
|
| NCI_Drug_Dictionary_ID |
791843 |
|
| PDQ_Closed_Trial_Search_ID |
791843 |
|
| PDQ_Open_Trial_Search_ID |
791843 |
|
| Preferred_Name |
Certolizumab Pegol |
|
| prefixIRI |
NCIT:C80972 |
|
| prefLabel |
Certolizumab Pegol |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C1872109 |
|
| subClassOf |